Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
NCT00742157
Terminated
Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN infusions/week.
Gender:
ALL
Ages:
Between 19 years and 78 years
Trial Updated:
08/26/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Short Bowel Syndrome
Register for Updates
Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
NCT04032717
Terminated
This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/05/2023
Locations: HIV/AIDS Clinical Research Unit / University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: HIV Prevention
Register for Updates
Assessment of Mechanisms of Improved Wound Healing
NCT00673309
Completed
The purpose of this study is to find ways to improve wound healing and decrease the negative effects of trauma from burn injury.
Gender:
ALL
Ages:
90 years and below
Trial Updated:
06/15/2023
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Burns
Register for Updates
Growth Hormone Replacement Therapy for Retried Professional Football Players
NCT04121780
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).
Gender:
MALE
Ages:
Between 18 years and 76 years
Trial Updated:
02/06/2023
Locations: Center for Neurolgoical Studies (CNS), Dearborn, Michigan
Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Register for Updates
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
NCT02217345
Completed
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/28/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
Register for Updates
Adult Growth Hormone Deficiency and Cardiovascular Risk
NCT00720902
Terminated
This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize that adults with growth hormone deficiency will have results suggestive of an increased risk for cardiovascular disease.
Gender:
ALL
Ages:
Between 19 years and 65 years
Trial Updated:
10/24/2022
Locations: Columbia University, College of Physicians and Surgeons, New York, New York
Conditions: Growth Hormone Deficiency
Register for Updates
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
NCT00608023
Completed
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/16/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama +46 locations
Conditions: Lipodystrophy, HIV Infections
Register for Updates
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
NCT03713957
Completed
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/05/2022
Locations: Clinical Trials, Inc., Little Rock, Arkansas +28 locations
Conditions: Parkinson Disease
Register for Updates
Growth Hormone for Osteoporosis Pseudoglioma Syndrome
NCT01614171
Withdrawn
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.
Gender:
ALL
Ages:
4 years and above
Trial Updated:
03/30/2022
Locations: University of Maryland School of Medicine, Baltimore, Maryland
Conditions: Osteoporosis Pseudoglioma Syndrome
Register for Updates
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
NCT01811576
Completed
The primary objective of this study is to evaluate the clinical effect of TV-1106.
Gender:
ALL
Ages:
Between 23 years and 65 years
Trial Updated:
12/08/2021
Locations: Teva Investigational Site 10564, Portland, Oregon +22 locations
Conditions: Growth Hormone Deficiency
Register for Updates
Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
NCT01169103
Completed
Teenagers and adults who are overweight or obese have an increase in fat in the abdomen, which increases their risk for diabetes and heart disease. Reducing abdominal fat is important to reduce risk for diabetes and for heart disease. Overweight teenagers also have low levels of growth hormone compared to normal weight teenagers, and teenagers with the lowest growth hormone levels also have the greatest abdominal fat. In children who are unable to make growth hormone for other reasons, giving ba... Read More
Gender:
FEMALE
Ages:
Between 13 years and 21 years
Trial Updated:
10/22/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Obesity
Register for Updates
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
NCT03765762
Completed
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Gender:
ALL
Ages:
Between 60 years and 95 years
Trial Updated:
01/08/2021
Locations: Cognitive Clinical Trials, Gilbert, Arizona +5 locations
Conditions: Severe Alzheimer Disease
Register for Updates